Abbott Announces Spin-off of its Nutrition Business
Abbott Laboratories, a prominent healthcare group headquartered in the United States, has announced the separation of its global nutrition business into a standalone, publicly traded company. This move is driven by the aim to address different investment identities, growth profiles, and innovation cycles.
The nutrition segment, which includes popular brands such as Similac, Ensure, PediaSure, Glucerna, and Pedialyte, generates approximately $8.5 billion in annual sales. The spin-off seeks to allow the new entity to strategically concentrate resources on innovation and key initiatives.
Robert Ford, Abbott's chairman and CEO, highlighted the growing demand for healthy nutrition as a unique opportunity for the nutrition unit. The new company will employ around 16,000 people and manage 14 manufacturing facilities.
Post-separation, Abbott intends to continue operating its core medical devices, diagnostics, and established pharmaceuticals businesses, which are expected to have annual sales of about $42 billion.
The spin-off will be executed through a tax-free distribution of shares to Abbott shareholders, and the transaction is anticipated to complete by the end of 2027. Daniel Salvadori, currently serving as Abbott's executive vice president and group president for established pharmaceuticals and nutritional products, is slated to become the CEO of the new nutrition company.
In its recent financial report, Abbott revealed that the nutrition unit's net sales declined by 1.3% to $6.42 billion in the first nine months of 2026. This was chiefly due to a 4.8% fall in US pediatric sales. Conversely, Abbott's total group net sales increased by 11.9% to $36.77 billion, supported by growth in diagnostics and medical devices. However, group operating earnings fell by 24.2% to $4.39 billion.
The announcement comes in the wake of Abbott settling legal issues related to a 2022 recall of infant formula, agreeing to pay $385 million to the US Department of Justice and settling additional claims for $670 million in August. The temporary closure of its Sturgis plant in Michigan due to contamination issues had earlier led to nationwide formula shortages.
